$RLAY
Relay Therapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023058237 Filed on November 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $25.55M $25.20M
YoY Change 9997.23% 7226.16%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $74.95M $18.49M
YoY Change 355.13% 15.03%
% of Gross Profit
Research & Development $330.0M $81.49M
YoY Change 390.54% 21.81%
% of Gross Profit
Depreciation & Amortization $1.379M $1.360M
YoY Change 18.27% 31.66%
% of Gross Profit
Operating Expenses $398.5M $98.78M
YoY Change 445.18% 14.54%
Operating Profit -$73.58M
YoY Change -14.34%
Interest Expense $31.05M $7.850M
YoY Change 477.9% 358.26%
% of Operating Profit
Other Income/Expense, Net -$18.00K $7.843M
YoY Change -25.0% 355.99%
Pretax Income -$342.0M -$65.73M
YoY Change 406.6% -21.91%
Income Tax
% Of Pretax Income
Net Earnings -$342.0M -$65.73M
YoY Change 406.6% -21.91%
Net Earnings / Revenue -1338.66% -260.83%
Basic Earnings Per Share -$0.54
Diluted Earnings Per Share -$2.79 -$0.54
COMMON SHARES
Basic Shares Outstanding 123.3M 122.1M
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $750.1M $810.6M
YoY Change -24.91% -23.08%
Cash & Equivalents $143.7M $151.3M
Short-Term Investments $606.4M $659.3M
Other Short-Term Assets $3.315M $3.678M
YoY Change 1.72% -68.24%
Inventory
Prepaid Expenses $16.70M $17.29M
Receivables $0.00 $211.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $770.1M $831.8M
YoY Change -24.46% -23.5%
LONG-TERM ASSETS
Property, Plant & Equipment $10.90M $10.70M
YoY Change -6.3% -6.05%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.707M $2.700M
YoY Change 5.0% 4.73%
Total Long-Term Assets $73.88M $75.16M
YoY Change -7.96% -7.69%
TOTAL ASSETS
Total Short-Term Assets $770.1M $831.8M
Total Long-Term Assets $73.88M $75.16M
Total Assets $844.0M $907.0M
YoY Change -23.26% -22.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.211M $13.35M
YoY Change -12.92% 40.78%
Accrued Expenses $14.89M $31.49M
YoY Change -34.41% 7.24%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $30.27M $50.75M
YoY Change -52.49% -28.95%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $61.71M $77.80M
YoY Change -28.12% -20.22%
Total Long-Term Liabilities $61.71M $77.80M
YoY Change -28.12% -20.22%
TOTAL LIABILITIES
Total Short-Term Liabilities $30.27M $50.75M
Total Long-Term Liabilities $61.71M $77.80M
Total Liabilities $91.98M $128.6M
YoY Change -38.5% -23.89%
SHAREHOLDERS EQUITY
Retained Earnings -$1.400B -$1.300B
YoY Change 27.27% 31.17%
Common Stock $127.0K $123.0K
YoY Change 4.96% 1.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $752.0M $778.4M
YoY Change
Total Liabilities & Shareholders Equity $844.0M $907.0M
YoY Change -23.26% -22.4%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$342.0M -$65.73M
YoY Change 406.6% -21.91%
Depreciation, Depletion And Amortization $1.379M $1.360M
YoY Change 18.27% 31.66%
Cash From Operating Activities -$89.19M -$75.40M
YoY Change 56.25% 13.99%
INVESTING ACTIVITIES
Capital Expenditures $116.0K $590.0K
YoY Change -94.99% -128.16%
Acquisitions
YoY Change
Other Investing Activities $59.80M $71.95M
YoY Change -141.35% 145.71%
Cash From Investing Activities $59.67M $71.37M
YoY Change -140.61% 162.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 21.91M 9.460M
YoY Change 1779.33% -96.69%
NET CHANGE
Cash From Operating Activities -89.19M -75.40M
Cash From Investing Activities 59.67M 71.37M
Cash From Financing Activities 21.91M 9.460M
Net Change In Cash -7.599M 5.430M
YoY Change -96.25% -97.8%
FREE CASH FLOW
Cash From Operating Activities -$89.19M -$75.40M
Capital Expenditures $116.0K $590.0K
Free Cash Flow -$89.30M -$75.99M
YoY Change 50.35% 18.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity File Number
EntityFileNumber
001-39385
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001812364
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2023#LicenseAndServiceMember
CY2022Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2023#LicenseAndServiceMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2023#LicenseAndServiceMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2023#LicenseAndServiceMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
RELAY THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3923475
dei Entity Address Address Line1
EntityAddressAddressLine1
399 Binney Street
dei Entity Address Address Line2
EntityAddressAddressLine2
2nd Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
370-8837
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
RLAY
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
123268740
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
151328000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
151794000
CY2023Q3 us-gaap Investments
Investments
659287000
CY2022Q4 us-gaap Investments
Investments
847123000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
211000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
306000
CY2022Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
4913000
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
17294000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
12110000
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
3678000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3259000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
831798000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1019505000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10701000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11634000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
59453000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
63754000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2707000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2578000
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2300000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2300000
CY2023Q3 us-gaap Assets
Assets
906959000
CY2022Q4 us-gaap Assets
Assets
1099771000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
13353000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10578000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
31486000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22703000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4785000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4276000
CY2023Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
24000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1100000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
26152000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
50748000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
63709000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
49815000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
53466000
CY2023Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
28023000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
32378000
CY2023Q3 us-gaap Liabilities
Liabilities
128586000
CY2022Q4 us-gaap Liabilities
Liabilities
149553000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
123161066
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
123161066
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
121112234
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
121112234
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
123000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
121000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2098723000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2019126000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3386000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10420000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1317087000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1058609000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
778373000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
950218000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
906959000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1099771000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25202000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
344000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25547000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1128000
CY2023Q3 us-gaap Revenues
Revenues
25202000
CY2022Q3 us-gaap Revenues
Revenues
344000
us-gaap Revenues
Revenues
25547000
us-gaap Revenues
Revenues
1128000
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
81494000
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
66900000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
252522000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
179078000
CY2023Q3 rlay Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-1200000
CY2022Q3 rlay Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
3262000
rlay Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-4355000
rlay Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-1133000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18485000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16074000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
58184000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
49607000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
98779000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
86236000
us-gaap Operating Expenses
OperatingExpenses
306351000
us-gaap Operating Expenses
OperatingExpenses
227552000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-73577000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-85892000
us-gaap Operating Income Loss
OperatingIncomeLoss
-280804000
us-gaap Operating Income Loss
OperatingIncomeLoss
-226424000
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
7845000
CY2022Q3 us-gaap Interest Income Other
InterestIncomeOther
1713000
us-gaap Interest Income Other
InterestIncomeOther
22345000
us-gaap Interest Income Other
InterestIncomeOther
3414000
CY2023Q3 rlay Other Income Expense
OtherIncomeExpense
-2000
CY2022Q3 rlay Other Income Expense
OtherIncomeExpense
7000
rlay Other Income Expense
OtherIncomeExpense
-19000
rlay Other Income Expense
OtherIncomeExpense
4000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7843000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1720000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
22326000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3418000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-65734000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-84172000
us-gaap Net Income Loss
NetIncomeLoss
-258478000
us-gaap Net Income Loss
NetIncomeLoss
-223006000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.76
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.76
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.04
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
122231255
CY2023Q3 rlay Weighted Average Number Of Shares Outstanding Diluted
WeightedAverageNumberOfSharesOutstandingDiluted
122231255
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
110905940
CY2022Q3 rlay Weighted Average Number Of Shares Outstanding Diluted
WeightedAverageNumberOfSharesOutstandingDiluted
110905940
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
121843116
rlay Weighted Average Number Of Shares Outstanding Diluted
WeightedAverageNumberOfSharesOutstandingDiluted
121843116
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
109290743
rlay Weighted Average Number Of Shares Outstanding Diluted
WeightedAverageNumberOfSharesOutstandingDiluted
109290743
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
2695000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-1483000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
7034000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-12301000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2695000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1483000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
7034000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-12301000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-63039000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-85655000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-251444000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-235307000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
950218000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1297000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21518000
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
4618000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-94239000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
883412000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
453000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1627000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23411000
CY2023Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-279000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-98505000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
810119000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9363000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
95000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21835000
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
2695000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-65734000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
778373000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
897808000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
883000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13455000
CY2022Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-8130000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-62046000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
841970000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
859000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1137000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15147000
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-2688000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-76788000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
779637000
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
284744000
CY2022Q3 rlay Issuance Of Common Stock Upon Milestone Achievement
IssuanceOfCommonStockUponMilestoneAchievement
6203000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1121000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13719000
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-1483000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-84172000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
999769000
us-gaap Net Income Loss
NetIncomeLoss
-258478000
us-gaap Net Income Loss
NetIncomeLoss
-223006000
us-gaap Share Based Compensation
ShareBasedCompensation
66764000
us-gaap Share Based Compensation
ShareBasedCompensation
42321000
us-gaap Depreciation
Depreciation
3894000
us-gaap Depreciation
Depreciation
2964000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
7094000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1567000
rlay Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-4355000
rlay Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-1133000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-95000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-162000
us-gaap Increase Decrease In Commodity Contract Assets And Liabilities
IncreaseDecreaseInCommodityContractAssetsAndLiabilities
-4913000
us-gaap Increase Decrease In Commodity Contract Assets And Liabilities
IncreaseDecreaseInCommodityContractAssetsAndLiabilities
339000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
5603000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
15159000
rlay Increase Decrease In Operating Lease Assets And Liabilities Net
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilitiesNet
-1159000
rlay Increase Decrease In Operating Lease Assets And Liabilities Net
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilitiesNet
6992000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2980000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
22000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-15427000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
27430000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
24000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-248000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-211128000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-172411000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4008000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6746000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
248727000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
207778000
us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
450691000
us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
172715000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
197956000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-41809000
rlay Proceeds From Issuance Of Common Stock Upon Follow On Offering Net
ProceedsFromIssuanceOfCommonStockUponFollowOnOfferingNet
284744000
rlay Proceeds From Issuance Of Common Stock Through At The Market Offering Net
ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingNet
9363000
rlay Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options
ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions
1845000
rlay Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options
ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions
2863000
rlay Proceeds From Employee Stock Purchase Plan
ProceedsFromEmployeeStockPurchasePlan
1627000
rlay Proceeds From Employee Stock Purchase Plan
ProceedsFromEmployeeStockPurchasePlan
1137000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12835000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
288744000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-337000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
74524000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
154372000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
282697000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
154035000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
357221000
rlay Periodic Change To Additions Of Property And Equipment In Accounts Payable And Accrued Expenses
PeriodicChangeToAdditionsOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses
-1047000
rlay Periodic Change To Additions Of Property And Equipment In Accounts Payable And Accrued Expenses
PeriodicChangeToAdditionsOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses
1065000
rlay Issuance Of Common Stock Upon Milestone Achievement
IssuanceOfCommonStockUponMilestoneAchievement
6203000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
46626000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
151328000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
354643000
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
2707000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
2578000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
154035000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
357221000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1300000000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the fair value of contingent milestone payments in connection with the acquisition of ZebiAI Therapeutics, Inc. ("ZebiAI"), the determination of the transaction price and standalone selling price of performance obligations under Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 606, </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> ("ASC 606"), the accrual of research and development and manufacturing expenses, the valuation of equity instruments, and the incremental borrowing rate for determining operating lease assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts, and experience.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
123
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
126
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.12
CY2023Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
29223000
CY2022Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
45863000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
32378000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
50258000
CY2023Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1200000
CY2022Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
3262000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-4355000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1133000
CY2022Q3 rlay Common Stock Issued Upon Milestone Achievement
CommonStockIssuedUponMilestoneAchievement
6203000
rlay Common Stock Issued Upon Milestone Achievement
CommonStockIssuedUponMilestoneAchievement
6203000
CY2023Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
28023000
CY2022Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
42922000
CY2023Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
28023000
CY2022Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
42922000
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
662673000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3386000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
659287000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
857543000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
108000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
10528000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
847123000
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
489766000
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
2038000
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
165726000
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
1348000
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
655492000
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
3386000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
333557000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
3509000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
372750000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
7019000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
706307000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
10528000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.12
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the stockholder to one vote on all matters submitted to a vote of the Company’s stockholders.
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21835000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13719000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
66764000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
42321000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-65734000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-84172000
us-gaap Net Income Loss
NetIncomeLoss
-258478000
us-gaap Net Income Loss
NetIncomeLoss
-223006000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.76
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.76
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.04
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
122231255
CY2023Q3 rlay Weighted Average Number Of Shares Outstanding Diluted
WeightedAverageNumberOfSharesOutstandingDiluted
122231255
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
110905940
CY2022Q3 rlay Weighted Average Number Of Shares Outstanding Diluted
WeightedAverageNumberOfSharesOutstandingDiluted
110905940
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
121843116
rlay Weighted Average Number Of Shares Outstanding Diluted
WeightedAverageNumberOfSharesOutstandingDiluted
121843116
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
109290743
rlay Weighted Average Number Of Shares Outstanding Diluted
WeightedAverageNumberOfSharesOutstandingDiluted
109290743
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19494538
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19494538
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12811599
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12811599
CY2022Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
4900000
rlay Contract With Customer Cash Received
ContractWithCustomerCashReceived
5000000
CY2023Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
rlay-20230930_cal.xml Edgar Link unprocessable
rlay-20230930_lab.xml Edgar Link unprocessable
0000950170-23-058237-index-headers.html Edgar Link pending
0000950170-23-058237-index.html Edgar Link pending
0000950170-23-058237.txt Edgar Link pending
0000950170-23-058237-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rlay-20230930.htm Edgar Link pending
rlay-20230930.xsd Edgar Link pending
rlay-ex10_1.htm Edgar Link pending
rlay-ex31_1.htm Edgar Link pending
rlay-ex31_2.htm Edgar Link pending
rlay-ex32_1.htm Edgar Link pending
Show.js Edgar Link pending
rlay-20230930_def.xml Edgar Link unprocessable
rlay-20230930_pre.xml Edgar Link unprocessable
rlay-20230930_htm.xml Edgar Link completed